eRF3a-GalNAc-ASO treatments led to dose-dependent liver target reduction in hemophilia mice, reducing eRF3a mRNA levels to ∼97%, 65%, 35%, and 19% with respect to the levels of DPBS-treated mice (Fig. 2A). Here, GSPT1 is linked to hemophilia.